R.H. Bluestein & Co’s GSK GSK Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q3 | $353K | Buy |
+12,000
| New | +$455K | 0.02% | 202 |
|
|
2022
Q2 | – | Sell |
-14,400
| Closed | -$784K | – | 378 |
|
|
2022
Q1 | $784K | Sell |
14,400
-80
| -0.6% | -$4.34K | 0.03% | 128 |
|
|
2021
Q4 | $798K | Sell |
14,480
-1,600
| -10% | -$83.2K | 0.03% | 135 |
|
|
2021
Q3 | $768K | Buy |
16,080
+4,000
| +33% | +$201K | 0.03% | 149 |
|
|
2021
Q2 | $601K | Sell |
12,080
-80
| -0.7% | -$3.84K | 0.02% | 199 |
|
|
2021
Q1 | $542K | Hold |
12,160
| – | – | 0.02% | 200 |
|
|
2020
Q4 | $559K | Sell |
12,160
-1,520
| -11% | -$69.8K | 0.02% | 177 |
|
|
2020
Q3 | $644K | Hold |
13,680
| – | – | 0.03% | 133 |
|
|
2020
Q2 | $698K | Buy |
13,680
+80
| +0.6% | +$4.1K | 0.04% | 117 |
|
|
2020
Q1 | $644K | Buy |
13,600
+1,600
| +13% | +$85.3K | 0.05% | 99 |
|
|
2019
Q4 | $705K | Hold |
12,000
| – | – | 0.04% | 120 |
|
|
2019
Q3 | $640K | Hold |
12,000
| – | – | 0.04% | 118 |
|
|
2019
Q2 | $600K | Hold |
12,000
| – | – | 0.03% | 127 |
|
|
2019
Q1 | $627K | Hold |
12,000
| – | – | 0.03% | 102 |
|
|
2018
Q4 | $573K | Hold |
12,000
| – | – | 0.04% | 94 |
|
|
2018
Q3 | $603K | Hold |
12,000
| – | – | 0.03% | 139 |
|
|
2018
Q2 | $605K | Hold |
12,000
| – | – | 0.03% | 125 |
|
|
2018
Q1 | $586K | Hold |
12,000
| – | – | 0.03% | 136 |
|
|
2017
Q4 | $532K | Sell |
12,000
-8,000
| -40% | -$370K | 0.03% | 141 |
|
|
2017
Q3 | $1.01M | Hold |
20,000
| – | – | 0.06% | 86 |
|
|
2017
Q2 | $1.08M | Sell |
20,000
-131
| -0.7% | -$6.98K | 0.06% | 72 |
|
|
2017
Q1 | $1.06M | Hold |
20,131
| – | – | 0.06% | 73 |
|
|
2016
Q4 | $969K | Hold |
20,131
| – | – | 0.06% | 71 |
|
|
2016
Q3 | $1.08M | Hold |
20,131
| – | – | 0.07% | 57 |
|
|
2016
Q2 | $1.09M | Hold |
20,131
| – | – | 0.08% | 49 |
|
|
2016
Q1 | $1.02M | Buy |
20,131
+131
| +0.7% | +$6.53K | 0.07% | 70 |
|
|
2015
Q4 | $1.01M | Hold |
20,000
| – | – | 0.06% | 79 |
|
|
2015
Q3 | $961K | Buy |
20,000
+4,000
| +25% | +$208K | 0.07% | 81 |
|
|
2015
Q2 | $833K | Buy |
16,000
+4,000
| +33% | +$225K | 0.05% | 109 |
|
|
2015
Q1 | $692K | Hold |
12,000
| – | – | 0.04% | 120 |
|
|
2014
Q4 | $641K | Sell |
12,000
-3,620
| -23% | -$203K | 0.04% | 147 |
|
|
2014
Q3 | $898K | Sell |
15,620
-4,000
| -20% | -$245K | 0.06% | 116 |
|
|
2014
Q2 | $1.31M | Sell |
19,620
-3,600
| -16% | -$244K | 0.08% | 89 |
|
|
2014
Q1 | $1.55M | Buy |
23,220
+4,780
| +26% | +$323K | 0.1% | 71 |
|
|
2013
Q4 | $1.23M | Sell |
18,440
-2,080
| -10% | -$135K | 0.08% | 90 |
|
|
2013
Q3 | $1.29M | Sell |
20,520
-1,500
| -7% | -$96.6K | 0.09% | 88 |
|
|
2013
Q2 | $1.38M | Buy |
+22,020
| New | +$1.4M | 0.12% | 74 |
|
Other funds holding GSK
R.H. Bluestein & Co's GSK Position: Q3 2022 in Review
R.H. Bluestein & Co opened a new position in GSK (GSK) in Q3 2022: 12,000 shares worth $353K. The stake represents 0.02% of the portfolio and ranks #202 among its holdings. This is a return to the name: R.H. Bluestein & Co previously reported a position in GSK as recently as Q1 2022.
R.H. Bluestein & Co first reported a position in GSK in Q2 2013 and has held it in 37 quarters since. The position peaked at $1.55M in Q1 2014. 742 funds tracked by Wall St. Rank hold GSK as of Q3 2022.
- R.H. Bluestein & Co held 12,000 shares of GSK worth $353K as of Q3 2022.
- GSK was a new R.H. Bluestein & Co position in Q3 2022.
- GSK made up 0.02% of R.H. Bluestein & Co's portfolio in Q3 2022, its #202 holding.
- R.H. Bluestein & Co first reported a position in GSK in Q2 2013 and has held it in 37 quarters since.
- R.H. Bluestein & Co's GSK position peaked at $1.55M in Q1 2014.
- 742 funds tracked by Wall St. Rank held GSK as of Q3 2022.
Based on R.H. Bluestein & Co's 13F filing for Q3 2022, filed 14 Nov 2022.